Harmony Biosciences CMO sells 38K shares
Harmony Biosciences’ chief medical officer exercised options for 38,452 HRMY shares and sold an equal number under a Rule 10b5-1 trading plan at weighted average prices near $43.
Rhea-AI Filing Summary
Harmony Biosciences Holdings, Inc. (HRMY) reported that its Chief Medical Officer, Kumar Budur, exercised stock options and sold shares over September 16–18, 2026. He exercised options covering 38,452 shares of Common Stock at exercise prices of $30.69 and $30.27, then sold 38,452 shares in open-market transactions at weighted average prices around $43 per share pursuant to a Rule 10b5-1 trading plan.
Positive
- None.
Negative
- None.
Insider Trade Summary
Exercise and Sale: 38,452 shares ($487K approx. pre-tax spread)
Exercise and Sale
15 txns
Insider
Budur Kumar
Role
CHIEF MEDICAL OFFICER
Sold
38,452 shs ($1.66M)
Approx. gross sale proceeds
$1.66M
Approx. exercise cost
$1.17M
Approx. pre-tax spread
$487K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option F4 | 10,406 | $0.00 | $0.00 |
| Exercise | Stock Option F5 | 25,446 | $0.00 | $0.00 |
| Exercise | Common Stock | 10,406 | $30.69 | $319K |
| Exercise | Common Stock | 25,446 | $30.27 | $770K |
| Sale | Common Stock F1, F3 | 35,852 | $43.0545 | $1.54M |
| Exercise | Stock Option F4 | 400 | $0.00 | $0.00 |
| Exercise | Stock Option F5 | 400 | $0.00 | $0.00 |
| Exercise | Common Stock | 400 | $30.69 | $12K |
| Exercise | Common Stock | 400 | $30.27 | $12K |
| Sale | Common Stock F1 | 800 | $43.00 | $34K |
| Exercise | Stock Option F4 | 900 | $0.00 | $0.00 |
| Exercise | Stock Option F5 | 900 | $0.00 | $0.00 |
| Exercise | Common Stock | 900 | $30.69 | $28K |
| Exercise | Common Stock | 900 | $30.27 | $27K |
| Sale | Common Stock F1, F2 | 1,800 | $43.0146 | $77K |
Holdings After Transaction:
Stock Option — 56,094 contracts (Direct);
Common Stock — 13,115 shares (Direct)
Footnotes (5)
- F1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
- F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.00 to $43.03. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.00 to $43.20. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F4. The stock option vests with respect to 25% of the underlying shares on January 24, 2025, with the remaining shares vesting ratably on a quarterly basis thereafter until the fourth anniversary of the grant date, subject to the Reporting Person's continued service through each applicable vesting date.
- F5. The stock option vests with respect to 25% of the underlying shares on May 1, 2025, with the remaining shares vesting ratably on a quarterly basis thereafter until the fourth anniversary of the grant date, subject to the Reporting Person's continued service through each applicable vesting date.
Key Figures
Shares sold: 38,452 shares
Shares exercised: 38,452 shares
Option exercise price: $30.69 per share
+4 more
7 metrics
Shares sold
38,452 shares
Common Stock sales by the Chief Medical Officer over September 16–18, 2026
Shares exercised
38,452 shares
Shares acquired through option exercises (code M) over the same period
Option exercise price
$30.69 per share
Stock options exercised into Common Stock, expiring January 24, 2034
Option exercise price
$30.27 per share
Stock options exercised into Common Stock, expiring May 1, 2034
Weighted average sale price
$43.01 per share
1,800-share sale on September 16, 2026, prices from $43.00 to $43.03
Weighted average sale price
$43.05 per share
35,852-share sale on September 18, 2026, prices from $43.00 to $43.20
Net buy/sell shares
38,452 shares net-sell
Transaction summary across all reported transactions
Key Terms
Rule 10b5-1 trading plan, weighted average price, stock option, derivative security
4 terms
Rule 10b5-1 trading plan regulatory
"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported in Column 4 is a weighted average price"
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
stock option financial
"The stock option vests with respect to 25% of the underlying shares"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
derivative security financial
"Exercise or conversion of derivative security"
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did HRMY’s Chief Medical Officer report on this Form 4?
The Chief Medical Officer, Kumar Budur, reported exercising stock options for 38,452 shares of Common Stock and selling 38,452 shares of Common Stock in open-market transactions over September 16–18, 2026.
At what prices were the HRMY stock options exercised by the CMO?
The reported stock options were exercised into Common Stock at exercise prices of $30.69 per share (expiring January 24, 2034) and $30.27 per share (expiring May 1, 2034).
Were the HRMY insider sales made under a Rule 10b5-1 trading plan?
Yes. A footnote states that the sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan, indicating they were pre-arranged under that plan.
AI-generated analysis. How Rhea-AI works. Not financial advice.
